Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q1 2017

Date: July 3, 2017
Pages: 89
Price:
US$ 1,500.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: P8194B972CFEN
Leaflet:

Download PDF Leaflet

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q1 2017
Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q1 2017

SUMMARY

GlobalData's 'Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q1 2017', report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q1 2017. The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

The pharmaceutical and healthcare industry reported a decrease in the number of deals and an increase in deal values in Q1 2017 with 1,142 deals worth USD95.5 billion, as compared 1,165 worth USD91.4 billion in Q1 2016. On a quarter-on-quarter basis, the number of deals and deal values increased in Q1 2017, when compared to 1,082 deals worth USD84.3 billion in Q4 2016. The pharmaceutical and healthcare industry reported a decrease in upfront payments in licensing agreements with USD731m in Q1 2017, as compared USD1.3 billion in Q1 2016. On a quarter-on-quarter basis, the upfront payments reported a decrease in Q1 2017, when compared to USD1 billion in Q4 2016. Deals in oncology therapeutics market registered an increase with 421 deals in Q1 2017, compared to 356 deals in Q4 2016.

SCOPE
  • Analysis of the market trends for the pharmaceutical industry in the global arena.
  • Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
  • Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
  • Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
  • Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
  • Analysis of partnership and licensing deals based on clinical stage of development of products.
  • Summary of the pharmaceutical deals globally in the five quarters.
  • Information on the top deals happened in the pharmaceutical industry.
  • Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
  • League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.
REASONS TO BUY
  • Enhance your decision making capability in a more rapid and time sensitive manner.
  • Find out the major deal performing segments for investments in your industry.
  • Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
  • Identify companies that are aggressively looking to raise capital in the market
  • Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
  • Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
  • Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
  • Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
  • Identify growth segments and opportunities in each region within the industry.
  • Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.
1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 PHARMACEUTICALS & HEALTHCARE, GLOBAL, DEAL SUMMARY, Q1 2017

2.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, Q1 2017
2.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, Q1 2017
2.3 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, Q1 2017
2.4 Pharmaceuticals & Healthcare, Global, Top Deals, Q1 2017
  2.4.1 Johnson & Johnson to Acquire Actelion for USD30 Billion
  2.4.2 Takeda Pharma Acquires Ariad Pharma for up to USD5.2 Billion in Tender Offer
  2.4.3 Pfizer Raises USD4.2 Billion in Public Offering of Notes
  2.4.4 Royalty Pharma Acquires Royalty Stream of Tysabri from Perrigo for USD2.85 Billion
  2.4.5 Fresenius Raises USD2.7 Billion in Private Placement of Notes

3 PHARMACEUTICALS & HEALTHCARE, GLOBAL, DEALS SUMMARY, BY TYPE

3.1 Pharmaceuticals & Healthcare, Global, M&A, Q1 2017
  3.1.1 Top M&A Deals in Q1 2017
  3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, Q1 2016 - Q1 2017
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q1 2017
  3.2.1 Top Initial Public Offerings in Q1 2017
  3.2.2 Top Secondary Offerings in Q1 2017
  3.2.3 Top PIPE Deals in Q1 2017
  3.2.4 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Q1 2016 - Q1 2017
3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, Q1 2017
  3.3.1 Top Venture Financing Deals in Q1 2017
  3.3.2 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q1 2017
  3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q1 2017
  3.3.4 Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, Q1 2016 - Q1 2017
  3.3.5 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Q1 2016 - Q1 2017
  3.3.6 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q1 2016 - Q1 2017
3.4 Pharmaceuticals & Healthcare, Global, Private Equity Deals, Q1 2017
  3.4.1 Top Private Equity Deals in Q1 2017
  3.4.2 Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Q1 2016 - Q1 2017

4 PHARMACEUTICALS & HEALTHCARE, GLOBAL, PARTNERSHIP DEALS, Q1 2017

4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q1 2017
4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Q1 2016 - Q1 2017
4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q1 2017
  4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, Q1 2017
  4.3.2 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q1 2017
  4.3.3 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payments, Q1 2017
4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), Q1 2016 - Q1 2017
4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, Q1 2016 - Q1 2017
4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), Q1 2016 - Q1 2017
4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q1 2016 - Q1 2017

5 PHARMACEUTICALS & HEALTHCARE, GLOBAL, LICENSING AGREEMENTS, Q1 2017

5.1 Pharmaceutical & Healthcare, Global, Licensing Agreements, Q1 2017
5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q1 2016 - Q1 2017
  5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Value, Q1 2017
  5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, Q1 2017
  5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q1 2017
5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q1 2016 - Q1 2017
5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payments Vs Milestone Payments (US$ m), Q1 2016 - Q1 2017
5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q1 2016 - Q1 2017
5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q1 2016 - Q1 2017
5.7 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payments Vs Milestone Payments (US$ m), Q1 2016 - Q1 2017

6 PHARMACEUTICALS & HEALTHCARE, GLOBAL, DEAL SUMMARY BY THERAPY AREA

6.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, Q1 2017
  6.1.1 Oncology - Deals of the Quarter
6.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, Q1 2017
  6.2.1 Central Nervous System - Deals of the Quarter
6.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, Q1 2017
  6.3.1 Infectious Disease - Deals of the Quarter
6.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, Q1 2017
  6.4.1 Immunology - Deals of the Quarter
6.5 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, Q1 2017
  6.5.1 Metabolic Disorders - Deals of the Quarter
6.6 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, Q1 2017
  6.6.1 Cardiovascular - Deals of the Quarter
6.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, Q1 2017
  6.7.1 Gastrointestinal - Deals of the Quarter
6.8 Pharmaceuticals & Healthcare, Global, Ophthalmology Deals, Q1 2017
  6.8.1 Ophthalmology - Deals of the Quarter
6.9 Pharmaceuticals & Healthcare, Global, Respiratory Deals, Q1 2017
  6.9.1 Respiratory - Deals of the Quarter
6.10 Pharmaceuticals & Healthcare, Global, Dermatology Deals, Q1 2017
  6.10.1 Dermatology - Deals of the Quarter

7 DEAL SUMMARY BY GEOGRAPHY

7.1 Pharmaceuticals & Healthcare, North America Region, Deals, Q1 2017
  7.1.1 North America - Deals of the Quarter
7.2 Pharmaceuticals & Healthcare, Europe Region, Deals, Q1 2017
  7.2.1 Europe - Deals of the Quarter
7.3 Pharmaceuticals & Healthcare, Asia-Pacific, Deals, Q1 2017
  7.3.1 Asia-Pacific - Deals of the Quarter
7.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, Q1 2017
  7.4.1 Rest of the World - Deals of the Quarter

8 PHARMACEUTICALS & HEALTHCARE, GLOBAL, TOP ADVISORS

8.1 Pharmaceuticals & Healthcare, Global Top Financial Advisors, M&A, Q1 2016 - Q1 2017
8.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Q1 2016 - Q1 2017

9 FURTHER INFORMATION

9.1 Methodology
9.2 About GlobalData
9.3 Contact Us
9.4 Disclosure information
9.5 Disclaimer

LIST OF TABLES

Table 1: Pharmaceuticals & Healthcare, Global, Deal Summary, Number of Deals and Deal Values (US$m), Q1 2016 - Q1 2017
Table 2: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), Q1 2017
Table 3: Pharmaceuticals & Healthcare, Global, Top Deals, Q1 2017
Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017
Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, Q1 2017
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, Q1 2016 - Q1 2017
Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$m), Q1 2016 - Q1 2017
Table 8: Pharmaceuticals & Healthcare, Global, Top Initial Public Offering Deals, Q1 2017
Table 9: Pharmaceuticals & Healthcare, Global, Top Secondary Offering Deals, Q1 2017
Table 10: Pharmaceuticals & Healthcare, Global, Top PIPE Deals, Q1 2017
Table 11: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$m), Q1 2016 - Q1 2017
Table 12: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017
Table 13: Pharmaceuticals & Healthcare, Global, Top Venture Capital Deals, Q1 2017
Table 14: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals and Deal Values (%), Q1 2017
Table 15: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q1 2016 - Q1 2017
Table 16: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017
Table 17: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q1 2016 - Q1 2017
Table 18: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017
Table 19: Pharmaceuticals & Healthcare, Global, Top Private Equity Deals, Q1 2017
Table 20: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q1 2016 - Q1 2017
Table 21: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017
Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017
Table 23: Pharmaceuticals & Healthcare, Partnership Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q1 2016 - Q1 2017
Table 24: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payments and Deal Values (US$ m), Q1 2017
Table 25: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q1 2017
Table 26: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, Q1 2017
Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q1 2016 - Q1 2017
Table 28: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q1 2016 - Q1 2017
Table 29: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Values (US$ m), Q1 2016 - Q1 2017
Table 30: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deal Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017
Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront & Milestone Payments and Deal Values (US$ m), Q1 2016 - Q1 2017
Table 32: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Deal Values, Q1 2017
Table 33: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Upfront Payment, Q1 2017
Table 34: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Milestone Payment, Q1 2017
Table 35: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017
Table 36: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment (US$ m), Q1 2016 - Q1 2017
Table 37: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q1 2016 - Q1 2017
Table 38: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment and Deal Values (US$ m), Q1 2016 - Q1 2017
Table 39: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017
Table 40: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017
Table 41: Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017
Table 42: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017
Table 43: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017
Table 44: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017
Table 45: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017
Table 46: Pharmaceuticals & Healthcare, Global, Ophthalmology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017
Table 47: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017
Table 48: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017
Table 49: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017
Table 50: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017
Table 51: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017
Table 52: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017
Table 53: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017
Table 54: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017

LIST OF FIGURES

Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$m), Q1 2016 - Q1 2017
Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), Q1 2017
Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), Q1 2017
Figure 4: Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$m), Q1 2016 - Q1 2017
Figure 5: Pharmaceuticals & Healthcare, Global, M&As, by Therapy Area, Number of Deals and Deal Values (US$m), by Therapy Area, Q1 2016 - Q1 2017
Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017
Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$m), Q1 2016 - Q1 2017
Figure 8: Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017
Figure 9: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%), Q1 2017
Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Deal Values (%), Q1 2017
Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q1 2016 - Q1 2017
Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017
Figure 13: Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017
Figure 14: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q1 2016 - Q1 2017
Figure 15: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017
Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017
Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront & Milestone Payment and Deal Values (US$ m), Q1 2016 - Q1 2017
Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q1 2016 - Q1 2017
Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q1 2016 - Q1 2017
Figure 20: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q1 2016 - Q1 2017
Figure 21: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payment and Deal Values (US$ m), Q1 2016 - Q1 2017
Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017
Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q1 2016 - Q1 2017
Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017
Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront & Milestone Payments and Deal Values (US$ m), Q1 2016 - Q1 2017
Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Number Of Deals, Q1 2016 - Q1 2017
Figure 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Deal Values (US$ m), Q1 2016 - Q1 2017
Figure 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q1 2016 - Q1 2017
Figure 29: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017
Figure 30: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017
Figure 31: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017
Figure 32: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017
Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017
Figure 34: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017
Figure 35: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017
Figure 36: Pharmaceuticals & Healthcare, Global, Ophthalmology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017
Figure 37: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017
Figure 38: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017
Figure 39: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017
Figure 40: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017
Figure 41: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017
Figure 42: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017
Figure 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017
Figure 44: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017
Skip to top


Ask Your Question

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q1 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: